$2.9 million gene therapy for severe hemophilia is approved by FDA
WASHINGTON — U.S. officials on Thursday approved drugmaker BioMarin's gene therapy for the most common form of hemophilia, a $2.9 million infused treatment that can significantly reduce dangerous bleeding problems. The Food and Drug Administration approved Roctavian for adult patients…